When an in-vitro protocol lists more than one peptide sequence, the laboratory may finish a session with several part-used vials and a practical question: can they be consolidated into one storage container, and does “no blended peptides” prevent that? The short answer is that consolidation is an inventory and storage decision, not permission to combine contents. A multi-sequence protocol calls for separate, traceable materials; it does not turn leftover vials into a custom blend. Research materials are for controlled laboratory and analytical research only, not for human or veterinary use, and all handling should follow the laboratory’s COSHH and safety procedures.
What “No Blended Peptides” Means in a Multi-Sequence Protocol
In catalogue terms, “no blended peptides” means the supplier does not sell a single vial containing two or more peptide sequences. Research Sciences states that it does not supply blended peptides, such as Ipamorelin plus CJC-1295, and advises purchasing each sequence separately and reserving any combination for a controlled experimental design. That distinction matters when a protocol lists several sequences: the list describes separate research materials, each with its own identity, lyophilised powder, vial label and batch documentation. It is not an instruction to create a mixture in the laboratory store. This is a documentation and compliance position as much as a catalogue one.
A common error is to read “consolidate” as “pool”. Leftover vials may be brought together in one box, drawer or storage container, but the contents should remain in their original vials. Emptying several sequences into one container would create an undocumented blend, obscure which certificate of analysis applies, and make it impossible to reconstruct the handling history of each material. Even where sequences are used in the same in-vitro study, the supplier’s role is to provide individual catalogue items; any combination belongs inside a controlled experimental design, not a storage shortcut.
For example, a protocol might list BPC-157 10mg, TB-500 5mg, Ipamorelin 5mg and CJC-1295 (No DAC) 5mg as separate research materials. Each should remain linked to its own SKU, expiry reference, batch CoA and internal test reference where applicable. A supplier such as Uk peptides lists compounds as separate catalogue items, and that separation is the point: it preserves identity and documentation. A researcher may store the vials together for convenience, but should not treat the shared store as a blended product.
Consolidating Leftover Vials Into One Store Without Combining Contents
Consolidating leftover vials into one store should mean one storage container, one shelf or one inventory location. It should not mean one vial. The original vial, cap and label are part of the material’s identity; they should stay intact, upright and protected from moisture, heat and light. For lyophilised materials, the shop’s handling guidance is storage at −20°C or below, sealed with desiccant where appropriate, and avoidance of repeated freeze–thaw cycles. If a material has been reconstituted for an in-vitro assay, the FAQ guidance points to 2–8°C for short-term laboratory use, with the understanding that reconstituted material is less stable.
Before placing several leftover vials into a single Storage Container, prepare an inventory sheet. Record the sequence name, catalogue reference, vial label reference, date received, date opened if relevant, storage location and the batch CoA or ITR associated with the material. The vial label reference format combines the SKU and expiry date, for example BPC10-03/27, and should be quoted when contacting the shop about documentation. Do not rely on cap colour to identify a sequence: the FAQs note that cap colours and packaging may vary, and that cap colour is not an indicator of identity, analytical quality or manufacturing origin.
Inside the container, use dividers, sealed secondary bags or clearly labelled compartments to keep vials physically separated. Do not top up an older vial with material from a newer delivery, even if the catalogue item has the same name; the FAQs explain that restocked products may share an ITR, but an ITR does not confirm that separate deliveries come from the same production lot or have had separate independent testing. Consolidate records, not powders. When removing material for an experiment, open only the required vial, work in a clean environment and take only the amount needed for that in-vitro workflow.
Documentation, Traceability and In-Vitro Handling After Consolidation
Documentation is what keeps a consolidated store defensible. Research Sciences describes a CoA for every product, with HPLC testing for purity and identity, and the homepage lists “CoAs Janoshik Analytical Reports”. Researchers should open the CoA that accompanies the specific batch and reconfirm current published wording on the live site, including any purity statement; the exact purity should be read from the batch CoA rather than assumed from a headline figure. If a product page or homepage lists ≥99% Verified Purity, treat that as the shop’s published figure at the time of reading and check the batch document supplied with the material.
A multi-sequence protocol should have a traceability map that follows each vial into the shared store. Link the physical vial to its label reference, CoA, ITR where present, and any internal laboratory record of reconstitution or use. If two sequences are stored in the same container, the map should make clear that they are separate materials with separate identities. That map also supports reproducibility: a later reviewer can see which sequence, batch and documentation applied to the material used in the in-vitro assay. Keep the map with the storage container or in the laboratory’s inventory system, and update it whenever a vial is removed, returned or depleted.
Handling after consolidation should remain an in-vitro laboratory workflow. Allow vials to reach room temperature before opening, work in a clean environment, and remove only the amount required for the experiment. Any reconstitution should be described in laboratory terms, such as diluent volume and target concentration for an in-vitro assay; the shop’s reconstitution calculator is for laboratory research use only and must not be used for human or veterinary dosing. Materials are not medicines, medical devices, injectables, treatments or food supplements, and they are not supplied for therapeutic, clinical or diagnostic purposes. The purchaser remains responsible for lawful use, safe handling, storage, disposal, COSHH compliance and checking suitability for the intended research application. Consolidating leftover vials into one store is therefore a record-keeping and containment exercise, not a blending step.
